University of Cincinnati's Professor of Psychiatry and Pediatrics: Melissa DelBello earned $215,174 income from Eli Lilly

Melissa DelBello Eli Lilly Q1 2011

$215,174.00







Image from ProPublica Dollars for Docs database

Does the University of Cincinnati consider Melissa DelBello's income from Eli Lilly to be a conflict of interest with regard to her clinical research at the University of Cincinnati?

"BACKGROUND, CURRENT PROJECTS, RESPONSIBILITIES

DR. MELISSA DELBELLO is a Professor of Psychiatry and Pediatrics. She is Vice-Chair of Clinical Research for the Department of Psychiatry, Co-Director of the Division of Bipolar Disorders Research, and Director of Reseach Training and Education for the Division of Child Psychiatry, Cincinnati Children’s Hospital Medical Center. Dr. DelBello received a B.S. from Cornell University, an M.D. from the University of Rochester School of Medicine, and an M.S. from the Division of Epidemiology and Biostatistics at the University of Cincinnati College of Medicine. Dr. DelBello’s research interests include the neurodevelopment and neuropharmacology of bipolar disorder."

Do you think Eli Lilly, the makers of the antipsychotic Zyprexa influence her research outcomes? Who makes $215,000 (nearly 1/4 million) in one 3 month period? will she earn the same the rest of 2011 to total a $ million dollars from Lilly personal income?

Does the University of Cincinnati have a policy for conflicts of interest? are the Professors allowed to receive money like this? does DelBello report it to the University and do they post it on their website for public viewing for transparency purpose?

Does the pharmaceutical income directly influence this part of her listed Curriculum Vitae ?

●Professional Advisory Board, Child and Adolescent Bipolar Foundation

●Editorial Board, J Clin Psychiatry, J Child Adolesc Psychopharmacol, Journal of Bipolar Disorders, Current Psychiatry

●Professional Advisory Board, Ohio Chapter of Depression and Bipolar Support Alliance

●Steering Committee, Modeling Effective Antipsychotic Therapeutic Success by Utilizing Real Evidence (MEASURE) Continue Medical Education Programs

●Scientific Advisory Board, Step Up for BP Kids (bipolar kids)

●Editorial Board, Bipolar Disorder

●Co-Chair, 31st Annual Review Course in Child and Adolescent Psychiatry, American Academy of Child and Adolescent Psychiatry, Cincinnati, OH

●Section Editor for Child and Adolescent Psychiatry, Bipolar Disorders

●Member, Neural Basis of Psychopathology, Addictions and Sleep Disorders (NPAS) Study Section, National Institute of Health

●Workgroup on Research, American Academy of Child and Adolescent Psychiatry

●Program Committee, American Academy of Child and Adolescent Psychiatry

●Chair, Institute Subcommittee, Program Committee, American Academy of Child and Adolescent Psychiatry


AWARDS & HONORS (selected)

●Lilly Fellowship Award, Society of Biological Psychiatry
●Medicine Laughlin Fellow, American College of Psychiatry
●Psychiatric Resident of the Year Program, Pfizer Pharmaceuticals
●Excellence in Psychiatry Award, Organon
●Presidential Scholar Award, American Academy of Child and Adolescent Psychiatry
●Lilly Pilot Research Award, American Academy of Child and Adolescent Psychiatry ●Fellowship in Child and Adolescent Depression, Klingenstein Third Generation Foundation
●Bristol-Myers Squibb Travel Award, American College of Neuropsychopharmaology
●Robinson-Cunningham Award, American Academy of Child and Adolescent Psychiatry
●Outstanding Mentor Award (twice), American Academy of Child and Adolescent Psychiatry
●Best Doctors in America, Best Doctors, Inc.
●Klerman Award for Outstanding Clinical Research, National Alliance for Research on Schizophrenia and Depression (NARSAD)
●Phenomenological, neurocognitive, and neuroimaging characterization of children at high risk for developing bipolar disorder. Theodore and Vada Stanley Foundation Research Award
●Quetiapine in the treatment of children and adolescents with mania associated with bipolar disorder. AstraZeneca
●Magnetic Resonance Spectroscopy and Olanzapine in bipolar adolescents at first hospitalization. Eli Lilly Inc.
●The neurochemistry and treatment of adolescent bipolar depression. Klingenstein Third Generation Foundation.
●Cerebellar abnormalities in adolescent bipolar disorder. NARSAD Young Investigator Award


Do you trust KOL's (Key Opinion Leaders)in psychiatry such as Melissa DelBello with this heavy of an influence from a pharmaceutical company that sells psychiatric medications to have untainted views, opinions or research study outcome?



Pharmaceutical Industry directly influencing Americas doctors

Current:

Melissa DelBello, Principal Investigator Zyprexa trial (Olanzapine)

Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults- Clinical Trials gov



University Of Cincinnati, Sponsor
Eli Lilly, Collaborator



ProPublica Dollars for Docs database, giving transparency and information to the American public so they can learn just how much power and influence the pharmaceutical industry has in the not so dark background.

Is your doctor a pharma income doctor?


Are you?